Close Menu

Oxford Nanopore

Oxford Nanopore Technologies was founded in 2005 to develop an electronic, single molecule sensing system based on nanopore science. The company now has more than 250 employees from multiple disciplines including nanopore science, molecular biology and applications, informatics, engineering, electronics, manufacturing and commercialization. Oxford Nanopore's instruments — MinIon, PromethIon, and GridIon are adaptable for the analysis of DNA, RNA, proteins, small molecules and other types of molecule.

Oxford Nanopore Facts

 

CEO: Gordon Sanghera

Website: www.nanoporetech.com

Ticker symbol: Privately held

Headquarters: Oxford, UK

Number of employees: 250+

Oxford Nanopore Flongle

The company is working on a variety of updates for existing platforms, including a disposable MinIon flow cell for diagnostic applications, as well as on new nanopore devices.

Two research groups demonstrated the de novo assembly of a human genome and a tomato genome, using data from Oxford Nanopore's MinIon.

Oxford Nanopore filed two lawsuits, one in the UK and one in Germany.

In Genome Research this week: longitudinal study of Burkholderia cenocepacia isolates from cystic fibrosis patients, long-read assembly approach, and more.

PacBio alleged in its suit that Oxford Nanopore is infringing on a patent it holds related to single-molecule nanopore sequencing.  

During a live webcast today, CTO Clive Brown provided updates on several products and processes, including the PromethIon, base calling, and 1D2 reads.

Two research groups reported on statistical methods for uncovering methylated cytosine and/or adenine bases using electrical current cues from Oxford Nanopore sequencers.

The researchers noted that the results "highlight the great potential of nanopore sequencing to analyze broad microbial community trends."

Researchers funded in part by Oxford Nanopore recently published a study showing nanopores can detect proteins at the single-molecule level.

Pages

The US Patent and Trademark Office is opening another interference proceeding in the CRISPR patent fight.

There's increasing genetic evidence that a number of ancient hominins may have contributed to the human gene pool, according to Discover's The Crux blog.

The Japan News writes that Japan needs to seize the opportunity to ensure that a wide number of people benefit from personalized cancer treatments.

In Cell this week: messenger RNA expression and translation, RNA localization atlas, and more.